Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20395893 | 0.97 | MAPT (0.44) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| Hydrogen Sulfide SCHEMBL20395882 | 0.95 | MAPT (0.43) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2527989 | 0.94 | CREBBP (0.41) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2525888 | 0.94 | FFAR1 (0.45) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5228091 | 0.92 | ADRB2 (0.40) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2532297 | 0.92 | ADRB2 (0.40) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL644523 | 0.92 | CA1 (0.43) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4878299 | 0.91 | KAT6A (0.51) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL642424 | 0.91 | CA12 (0.56) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2533186 | 0.90 | ADRB2 (0.39) | MAPTPOLBSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999716-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| WO-2017093157-A1 | PIPERIDINE, PYRROLIDINE AND 2-OXO-1,3-OXAZINANE DERIVATIVES AS INHIBITORS OF BACTERIAL EFFLUX-PUMPS FOR THE TREATMENT OF MICROBIAL INFECTIONS | BASILEA PHARMACEUTICA AG (CH) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017042099-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| CN-102958912-B | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2015-01-14 | — | — | CN | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| CN-102958912-A | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-03-06 | — | — | CN | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| CN-1319198-A | Liquid crystal aligning agent, liquid crystal cell using the same, and method for aligning liquid crystal | NISSAN CHEMICAL IND LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
| EP-1111442-A1 | TREATING AGENT FOR LIQUID CRYSTAL ALIGNMENT LAYER AND LIQUID CRYSTAL DEVICE USING THE SAME, AND METHOD FOR ALIGNMENT OF LIQUID CRYSTAL | Nissan Chemical Industries, Ltd. (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-4975490-A | Phthalic acid ester-modified organopolysiloxane and method for its preparation | TORAY SILICONE COMPANY, LTD. (JP) | 1990-12-04 | — | — | US | disclosed |
| US-4924020-A | Phthalic acid ester-modified organopolysiloxane and method for its preparation | TORAY SILICON COMPANY, LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| EP-0316915-A2 | Phthalic acid ester-modified organopolysiloxane and method for its preparation | TORAY SILICONE COMPANY, LIMITED (JP) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | MAPT 1537/4885POLB 3329/4885SMN1; SMN2 2067/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | MAPT 659/4885POLB 3928/4885SMN1; SMN2 1279/4885 |
| US-11999716-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | MAPT 1526/4885POLB 3319/4885SMN1; SMN2 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.